Clinical Trials

Clinical trials are an extremely important component of cancer care. According to National Comprehensive Cancer Network Guidelines, "the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged." Drs. Brown and Gold actively pursues this mission. Dr. Brown is the Beaumont Hospital Co-PI to NCORP (NCI Community Oncology Research Program) and is the PI (Priniciple Investigator) at Beaumont Health of many of the clinical trials offered by cooperative groups in the U.S. (NSABP, SWOG, Alliance)

Multiple clinical trials are available through the NCI (National Cancer Institute). Dr. Brown is Principle Investigator at Beaumont Hospital, Troy (Beaumont Cancer Institute) for a number of these trials. Here is a list of Breast Cancer related Clinical Trials available, as of December, 2015:

ALLIANCE A011202: A RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF AXILLARY LYMPH NODE DISSECTION IN BREAST CANCER PATIENTS (CT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY).
ECOG E1Z11: A COHORT STUDY TO EVALUATE GENETIC PREDICTORS OF AROMATASE INHIBITOR MUSCOLOSKELETAL SYMPTOMS (AIMSS).
ECOG-ACRIN EAY131(MATCH): MOLECULAR ANALYSIS FOR THERAPY CHOICE (MATCH)
NRG-BR002: A PHASE IIR/III TRIAL OF STANDARD OF CARE THERAPY WITH OR WITHOUT STEREOTACTIC BODY RADIOTHERAPY (SBRT) AND/OR SURGICAL ABLATION FOR NEWLY OLIGOMETASTATIC BREAST CANCER.
NSABP B-51: A RANDOMIZED PHASE III CLINICAL TRIAL EVALUATING POST-MASTECTOMY CHESTWALL AND REGIONAL NODAL XRT AND POST-LUMPECTOMY REGIONAL NODAL XRT IN PATIENTS WITH POSITIVE AXILLARY NODES BEFORE NEOADJUVANT CHEMOTHERAPY WHO CONVERT TO PATHOLOGICALLY NEGATIVE AXILLARY NODES AFTER NEOADJUVANT CHEMOTHERAPY.
ALLIANCE A011502 RAMDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR HER 2 NEGATIVE BREAST CANCER: THE ABC TRIAL
ALLIANCE A011401 RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
Cascadian Therapeutics Inc/Oncothyreon ONT-380-206 (HER2CLIMB) PHASE II RANDOMIZED, DOUBLE-BLINDED, CONTROLLED STUDY OF ONT-380 VS. PLACEBO IN COMBINATION WITH CAPECITABINE AND TRASTUZUMAB IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CARCINOMA

NSABP B-55/BIG 6-13: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED MULTI-CENTRE PHASE III STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLAPARIB VERSUS PLACEBO AS ADJUVANT TREATMENT TREATMENT IN PATIENTS WITH GERMLINE BRCA1/2 MUTATIONS AND HIGH RISK HER2 NEGATIVE PRIMARY BREAST CANCER WHO HAVE COMPLETED DEFINITIVE LOCAL TREATMENT AND NEOADJUVANT OR ADJUVANT CHEMOTHERAPY.
SWOG S1207: PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.
SWOG S1416: PHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CISPLATIN WITH OR WITHOUT ABT-888 (VELIPARIB) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND/OR BRCA MUTATION-ASSOCIATED BREAST CANCER
HIC #2012-064: A PHASE II RANDOMIZED TRIAL USING CALENDULA SPRAY COMPARED WITH STANDARD OF CARE FOR THE PREVENTION OF ACUTE RADIATION DERMATITIS IN PATIENTS RECEIVING BREAST CONSERVING THERAPY WITH WHOLE BREAST IRRADIATION.
WAKE FOREST 98213 (PREVENT) – PREVENTING ANTHRACYCLINE CARDIOVASCULAR TOXICITY WITH STATINS
CTSU DCP-001: USE OF A CLINICAL TRIAL SCREENING TOOL TO ADDRESS CANCER HEALTH DISPARITIES IN THE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (NCORP)
Beaumont’s NCI Community Oncology Research Program (NCORP) is a project supported by Award 1UG1CA190002 from the National Cancer Institute. Additional support is given by the Beaumont Research Institute and Beaumont Health System. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.